Pfizer has secured approval from the FDA for its Prevnar 20 pneumococcal disease vaccine for infants, children and adolescents
The approval will allow the vaccine to be used in infants as young as 6 weeks. It was already approved for adults.
Prevnar 20 is designed to prevent invasive pneumococcal disease.